Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label first-line R-FC induction followed by rituximab maintenance in chronic lymphocytic leukemia
2007-002733-36Phase 2Completed
- Sponsor
- Roche
- Start
- Jul 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Roche. Primary endpoints: Complete response rate after R-FC induction and Minimal residual disease-negative response rate after R-FC. Started Jul 2007; status: completed.
02
Drugs
rituximab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2007-002733-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002733-36.